Inovio Pharmaceuticals (INO) Payables (2010 - 2026)

Inovio Pharmaceuticals has disclosed Payables across 17 years of filings, most recently posting $36.7 million for Q2 2026.

• In Q2 2026, Payables rose 34.99% year-over-year to $36.7 million; the TTM figure through Jun 2026 stood at $36.7 million (up 34.99% YoY), while the FY2025 annual figure was $40.1 million, up 36.21% from the prior year.
• Payables came in at $36.7 million for Q2 2026 at Inovio Pharmaceuticals, up from $34.2 million in the prior quarter.
• In the past five years, Payables ranged from a high of $106.4 million in Q2 2022 to a low of $14.7 million in Q3 2024.
• Average Payables over 5 years is $38.3 million, with a median of $28.3 million recorded in 2024.
• Year-over-year, Payables slumped 80.01% in 2023 and surged 345.68% in 2025.
• Over 5 years, Payables stood at $80.9 million in 2022, then plunged by 75.47% to $19.8 million in 2023, then jumped by 48.41% to $29.5 million in 2024, then soared by 36.21% to $40.1 million in 2025, then declined by 8.58% to $36.7 million in 2026.
• Per Business Quant data, the three most recent Payables figures were $36.7 million in Q2 2026, $34.2 million in Q1 2026, and $40.1 million in Q4 2025.